Literature DB >> 2184507

Efficacy of fluconazole in prophylaxis and treatment of experimental Candida endocarditis.

L P Longman1, S A Hibbert, M V Martin.   

Abstract

The efficacy of fluconazole, a bis-triazole antifungal agent, for prophylaxis and treatment of endocarditis due to Candida albicans and Candida parapsilosis is assessed in a rabbit model. Fourteen daily injections of fluconazole at doses of 20 and 10 mg/kg of body weight eradicated C. albicans and C. parapsilosis, respectively, from the cardiac vegetations in all animals tested. Amphotericin B (3 mg/kg) and flucytosine (35 mg/kg) both singly and in combination failed to achieve eradication in 100% of the animals. A two-dose prophylactic regimen of 30 mg of fluconazole/kg was consistently successful in preventing experimental endocarditis caused by C. albicans or C. parapsilosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184507     DOI: 10.1093/clinids/12.supplement_3.s294

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  4 in total

Review 1.  Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review.

Authors:  D C B Lye; A Hughes; D O'Brien; E Athan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

2.  Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits.

Authors:  K Chemlal; L Saint-Julien; V Joly; R Farinotti; N Seta; P Yeni; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 3.  Fungal endocarditis--a report on seven cases and a brief review.

Authors:  H Hogevik; K Alestig
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

4.  Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis.

Authors:  M D Witt; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.